One-year outcomes from the 750-patient, randomized PORTICO IDE trial show Abbott Laboratories Inc.’s Portico TAVR system is non-inferior to Edwards Lifesciences Corp.'s Sapien and Medtronic PLC’s CoreValve TAVR systems in patients with high or extreme surgical risk.
Greg Fontana of the Cardiovascular Institute of Los Robles in Thousand Oaks, CA, presented the results at the Transcatheter Cardiovascular Therapeutics (TCT)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?